A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Inclusion Criteria: * Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive * BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg Exclusion Criteria: * History of any clinically important disease or disorder * History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones * Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day * Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis * Any clinically significant abnormal findings in vital signs * Any clinically significant abnormalities on 12-lead ECG * HbA1c ≥6.5% (≥48 mmol/mol) * Evidence of renal impairment * Females who are pregnant or lactating. * Any participant who has received an amylin analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) * Participants who report to have previously received AZD6234. * Use of any prescribed or non-prescribed medication